Abiomed CEO Michael Minogue appointed as AdvaMed chairperson
Tuesday, February 23, 2021
Minogue will serve as chairperson of the trade association’s board of directors for two years. He has been a member of the board since 2007 and a member of the board executive committee since 2009.
Throughout his tenure at AdvaMed, Minogue has served on several committees, including those overseeing membership, inclusion and diversity, payment policy, ethics and international policy. He was elected as the first chairperson of the newly created emerging growth company council (now AdvaMed Accel) in 2011 and served as the chairperson until 2014. He also co-founded MedTechVets.org, which is served as chairperson until 2019.
Minogue has also been president and CEO of Abiomed for 17 years. Prior to joining the company, he held numerous leadership roles at General Electric Medical Systems.
“This past year, the medical technology community rose to the challenge presented by COVID-19. Our companies produced the PPE, diagnostic COVID-19 tests, and medical devices needed to help COVID-19 patients. Our employees continued to make life-saving products and support hospitals all over the world. I’m humbled and thankful for the opportunity to serve as Chairman of Advamed during this time. I hope to help our industry continue to improve and save patients’ lives,” Minogue said in a press release.
As AdvaMed’s chairperson, Minogue plans to strengthen the association’s and industry’s focus on patients and will build upon outgoing chairperson Kevin Lobo’s leadership and successful work to improve inclusion and diversity in the industry. He will also expand recruitment from the nation’s military veterans.
“Our nation’s military veterans are highly diverse and have a desire to continue to serve a purpose. This makes veterans an ideal match for our industry that is committed to serving others around the world,” Minogue said.
“There’s no one better prepared to lead this association for the next two years than Mike. As a leader in our industry for more than two decades with a career that spans small, midsize, and larger company perspectives, and with his distinguished service in the military, Mike brings tremendous experience, and a focus on patients that I know will benefit them and the companies innovating on their behalf. Mike’s emphasis on putting patients first is a great example for our industry, and I know I speak for the entire Board when I say we look forward to his leadership,” AdvaMed president and CEO Scott Whitaker said.
- Creation of the MedDevice Network to connect companies with suppliers outside of the medtech industry to improve the ability to meet high demands for COVID-related medical supplies
- Creation of the COVID-19 Testing Supply Registry to help federal and state governments get a better understanding of the nation’s testing needs
- Full repeal of the medical device excuse tax
- Secured federal establishment of a new coverage pathway for breath through medical technologies
- Launched The Story of Medtech, which hosts nearly 100 unique stories about patients who have benefited from medtech innovation
- Introduced Safety.AdvaMed.Org to describe the safety and efficacy standards medtech companies are held to
- Released a new research study to outline steps CMS, HHS and Congress might take to modernize the Medicare framework for coverage and payment of digital health technologies
- Launched AdvaMed Advance
- Board approval of AdvaMed’s principles on health equity.
“Kevin led our association through the most difficult time our industry has seen in our lifetime. Kevin’s leadership was crucial—steady, innovative, and forward-thinking. Under his leadership, AdvaMed rallied to respond to the COVID-19 pandemic, from ensuring the supply of critical medical supplies, such as PPE and diagnostic tests, to partnering with Government to ensure timely granting of emergency use approvals. He also championed diversity, equity and inclusion as well as patient advocacy. We thank him for his leadership and guidance, which will have a lasting impact on the industry and the patients we serve,” Whitaker said.